Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis

T. Kato, K. Kurita, T. Seino, T. Kadoya, H. Horie, M. Wada, T. Kawanami, M. Daimon, A. Hirano

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In amyotrophic lateral sclerosis (ALS), abnormal accumulation of neurofilaments induces pathological changes such as axonal spheroids, cord-like neurite swellings, and perikaryal conglomerate inclusions in degenerating motor neurons of the spinal cord, and the accumulation seems to cause motor neuron degeneration in this disease. Such ALS lesions were intensely labeled with HepSS-1, a monoclonal antibody to heparan sulfate. Since the identification of HepSS-1-immunoreactive substance seems to be an important step for understanding the molecular pathology of ALS, we purified the substance from human spinal cord tissue to homogeneity. Amino acid sequence of the protein was consistent with that of galectin-1. Immunohistochemistry using antibodies against recombinant human galectin-1 showed that galectin-1 was accumulated in these lesions in ALS. Although HepSS-1 was believed to be specific for heparan sulfate, it reacted with recombinant human galectin-1 which has no heparan sulfate moiety. The results show that galectin-1 is a component of the neurofilamentous lesions in ALS. Since galectin-1 has axonal regeneration-enhancing activity, the abnormal accumulation of galectin-1 to the lesions seems to be related to the pathological process of ALS.

Original languageEnglish (US)
Pages (from-to)166-172
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume282
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Galectin 1
Amyotrophic Lateral Sclerosis
Heparitin Sulfate
Neurons
Motor Neurons
Spinal Cord
Pathology
Nerve Degeneration
Intermediate Filaments
Molecular Pathology
Neurites
Pathologic Processes
Swelling
Monoclonal Antibodies
Amyotrophic lateral sclerosis 1
Regeneration
Amino Acid Sequence
Tissue
Amino Acids
Immunohistochemistry

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis. / Kato, T.; Kurita, K.; Seino, T.; Kadoya, T.; Horie, H.; Wada, M.; Kawanami, T.; Daimon, M.; Hirano, A.

In: Biochemical and Biophysical Research Communications, Vol. 282, No. 1, 2001, p. 166-172.

Research output: Contribution to journalArticle

Kato, T, Kurita, K, Seino, T, Kadoya, T, Horie, H, Wada, M, Kawanami, T, Daimon, M & Hirano, A 2001, 'Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis', Biochemical and Biophysical Research Communications, vol. 282, no. 1, pp. 166-172. https://doi.org/10.1006/bbrc.2001.4556
Kato, T. ; Kurita, K. ; Seino, T. ; Kadoya, T. ; Horie, H. ; Wada, M. ; Kawanami, T. ; Daimon, M. ; Hirano, A. / Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis. In: Biochemical and Biophysical Research Communications. 2001 ; Vol. 282, No. 1. pp. 166-172.
@article{5a83fb555cde480ebaef0245d5f43f1c,
title = "Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis",
abstract = "In amyotrophic lateral sclerosis (ALS), abnormal accumulation of neurofilaments induces pathological changes such as axonal spheroids, cord-like neurite swellings, and perikaryal conglomerate inclusions in degenerating motor neurons of the spinal cord, and the accumulation seems to cause motor neuron degeneration in this disease. Such ALS lesions were intensely labeled with HepSS-1, a monoclonal antibody to heparan sulfate. Since the identification of HepSS-1-immunoreactive substance seems to be an important step for understanding the molecular pathology of ALS, we purified the substance from human spinal cord tissue to homogeneity. Amino acid sequence of the protein was consistent with that of galectin-1. Immunohistochemistry using antibodies against recombinant human galectin-1 showed that galectin-1 was accumulated in these lesions in ALS. Although HepSS-1 was believed to be specific for heparan sulfate, it reacted with recombinant human galectin-1 which has no heparan sulfate moiety. The results show that galectin-1 is a component of the neurofilamentous lesions in ALS. Since galectin-1 has axonal regeneration-enhancing activity, the abnormal accumulation of galectin-1 to the lesions seems to be related to the pathological process of ALS.",
author = "T. Kato and K. Kurita and T. Seino and T. Kadoya and H. Horie and M. Wada and T. Kawanami and M. Daimon and A. Hirano",
year = "2001",
doi = "10.1006/bbrc.2001.4556",
language = "English (US)",
volume = "282",
pages = "166--172",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis

AU - Kato, T.

AU - Kurita, K.

AU - Seino, T.

AU - Kadoya, T.

AU - Horie, H.

AU - Wada, M.

AU - Kawanami, T.

AU - Daimon, M.

AU - Hirano, A.

PY - 2001

Y1 - 2001

N2 - In amyotrophic lateral sclerosis (ALS), abnormal accumulation of neurofilaments induces pathological changes such as axonal spheroids, cord-like neurite swellings, and perikaryal conglomerate inclusions in degenerating motor neurons of the spinal cord, and the accumulation seems to cause motor neuron degeneration in this disease. Such ALS lesions were intensely labeled with HepSS-1, a monoclonal antibody to heparan sulfate. Since the identification of HepSS-1-immunoreactive substance seems to be an important step for understanding the molecular pathology of ALS, we purified the substance from human spinal cord tissue to homogeneity. Amino acid sequence of the protein was consistent with that of galectin-1. Immunohistochemistry using antibodies against recombinant human galectin-1 showed that galectin-1 was accumulated in these lesions in ALS. Although HepSS-1 was believed to be specific for heparan sulfate, it reacted with recombinant human galectin-1 which has no heparan sulfate moiety. The results show that galectin-1 is a component of the neurofilamentous lesions in ALS. Since galectin-1 has axonal regeneration-enhancing activity, the abnormal accumulation of galectin-1 to the lesions seems to be related to the pathological process of ALS.

AB - In amyotrophic lateral sclerosis (ALS), abnormal accumulation of neurofilaments induces pathological changes such as axonal spheroids, cord-like neurite swellings, and perikaryal conglomerate inclusions in degenerating motor neurons of the spinal cord, and the accumulation seems to cause motor neuron degeneration in this disease. Such ALS lesions were intensely labeled with HepSS-1, a monoclonal antibody to heparan sulfate. Since the identification of HepSS-1-immunoreactive substance seems to be an important step for understanding the molecular pathology of ALS, we purified the substance from human spinal cord tissue to homogeneity. Amino acid sequence of the protein was consistent with that of galectin-1. Immunohistochemistry using antibodies against recombinant human galectin-1 showed that galectin-1 was accumulated in these lesions in ALS. Although HepSS-1 was believed to be specific for heparan sulfate, it reacted with recombinant human galectin-1 which has no heparan sulfate moiety. The results show that galectin-1 is a component of the neurofilamentous lesions in ALS. Since galectin-1 has axonal regeneration-enhancing activity, the abnormal accumulation of galectin-1 to the lesions seems to be related to the pathological process of ALS.

UR - http://www.scopus.com/inward/record.url?scp=0034805158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034805158&partnerID=8YFLogxK

U2 - 10.1006/bbrc.2001.4556

DO - 10.1006/bbrc.2001.4556

M3 - Article

VL - 282

SP - 166

EP - 172

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -